- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lannett Will Discuss Insulin Glargine Application With FDA
Longtime generics manufacturer Lannett is moving an insulin glargine biosimilar development plan forward and announced an upcoming meeting with the FDA. The agent would compete with the reference product Lantus.
Longtime generic drug manufacturer Lannett said it would meet with the FDA June 9, 2020, to plan the next steps for clinical advancement of its planned insulin glargine biosimilar. Insulin glargine is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Under a March 23, 2020, change in the approval pathway for insulin products, insulin glargine is now considered a biologic and must be reviewed under section 351 of the Public Health Service Act. Lannett, of Philadelphia, Pennsylvania, is developing the insulin product in a partnership with the HEC Group of companies.
Tim Crew, chief executive officer of Lannett, said the meeting with the FDA is expected to result in specific guidance that will clarify the requirements for a successful biologics license application.
"We expect our discussion with the FDA to include the design and endpoint of any additional human studies required for filing a Biologics License Application (BLA) and approval of insulin glargine as a biosimilar," he said.
In December 2019, Lannett announced positive results from the first human study evaluating insulin glargine. The company said that in terms of pharmacokinetics and pharmacodynamics, the trial confirmed that the Lannett/HEC biosimilar insulin glargine is equivalent to the reference product Lantus. Lannett said the study met all primary end points.
"With the positive data from this human clinical trial, combined with the earlier comparative analytical assessment and animal studies, we are building certainty around our development program," Crew said at that time.
Kristin Arnold, PhD, Lannett’s vice president of research and development, said the biosimilar insulin candidate product was safe and well tolerated, with no serious adverse events or serious drug reactions observed during the study.
Lannett, founded in 1942, develops, manufactures, packages, markets, and distributes generic pharmaceutical products for a wide range of medical indications.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
